Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC
The results of a randomized, double-blind phase 3 study established the equivalence of bevacizumab reference to its biosimilar MIL60 in terms of clinical efficacy, safety, population pharmacokinetics, and immunogenicity in patients with nonsquamous NSCLC.
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
The results of a noninterventional, retrospective study showed that rituximab originator and the rituximab-abbs biosimilars yielded comparable efficacy and tolerability in the first-line treatment of patients with CLL and NHL, with rituximab-abbs use resulting in cost-savings.
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
Findings from modeling studies support adjuvant continuation of pertuzumab plus trastuzumab for patients achieving pathologic complete response among patients with high-risk, HER2-positive early breast cancer.
Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL
Real-world outcomes from a retrospective, single-center study suggested that pegfilgrastim or its biosimilar pegfilgrastim-cbqv does not increase febrile neutropenia or delayed engraftment risk in patients with lymphoma and CLL and may be safe to use after administration of chemotherapy.
Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma
The results of a retrospective, single-center analysis demonstrated that same-day pegfilgrastim or pegfilgrastim-cbqv was safe and effective in patients with diffuse large B-cell lymphoma who received a rituximab plus miniCHOP chemotherapy regimen, with no significant increase in febrile neutropenia or delayed engraftment.
Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics
Real-world evidence demonstrated that the characteristics of patients with metastatic colorectal cancer who received bevacizumab-awwb in the first year after product launch were similar regardless of prior bevacizumab use, and that bevacizumab-awwb was used in new and continuing patients.
Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors
An observational study indicates that the Oncology Care Model led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use.
Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment
The findings of a simulation modeling analysis demonstrate that conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb provides significant cost-savings, which could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy in patients with diffuse large B-cell lymphoma.
Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
A pharmacokinetic study demonstrated bioequivalence between SB12 and the eculizumab reference products, along with comparable pharmacodynamics, safety, and immunogenicity.
Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell NHL
The preliminary results of a phase 2 study indicate that the combination of rituximab biosimilar plus pegylated interferon α-2b was well-tolerated and yielded responses in newly diagnosed advanced indolent B-cell NHL.
Page 1 of 7
Results 1 - 10 of 61
Results 1 - 10 of 61